Comparison of stroke and major bleeding risk of treatment with apixaban vs. rivaroxaban and dabigatran among elderly nonvalvular atrial fibrillation patients in the United States

Back

ESC Premium Access

Comparison of stroke and major bleeding risk of treatment with apixaban vs. rivaroxaban and dabigatran among elderly nonvalvular atrial fibrillation patients in the United States

Session: Anticoagulation in atrial fibrillation

Topic: Atrial fibrillation (AF)

Speaker: Doctor S. Deitelzweig (New Orleans, US)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Doctor Steven Deitelzweig

Ochsner Medical Center, New Orleans (United States of America)

7 presentations

0 follower

9 more presentations in this session

Atrial fibrillation and venous thromboembolism. a Swedish nationwide registry study on 1358274 individuals.

Speaker: Assistant Professor B. Hornestam (Gothenburg, SE)

Higher risk of dementia without oral anticoagulation in atrial fibrillation

Speaker: Associate Professor L. Friberg (Stockholm, SE)

Anticoagulant use and associated outcomes in patients with atrial fibrillation and advanced kidney disease

Speaker: Doctor P. Noseworthy (Rochester, US)

Age and gender differences in stroke and bleeding risks in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants

Speaker: Doctor P. Noseworthy (Rochester, US)

Similar long-term risk of thromboembolic events in postoperative atrial fibrillation following coronary artery bypass grafting and non-valvular atrial fibrillation: need for anticoagulation?

Speaker: Mr J. Butt (Copenhagen, DK)

Access the full session

Anticoagulation in atrial fibrillation

Speakers: Doctor S. Deitelzweig, Assistant Professor B. Hornestam, Associate Professor L. Friberg, Doctor P. Noseworthy, Doctor P. Noseworthy...

Access

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources